https://allsci.com/news/licensing-and-partnerships/lnp-chemistry-car-platform-create-medicines/ AllScien 2026-07-31T16:53:13.305621Z CREATE Medicines licenses Monash's targeted LNP chemistry to expand in vivo CAR platform https://allsci.com/news/licensing-and-partnerships/senaparib-license-agreement-impact-therapeutics/ AllScien 2026-07-31T16:43:12.072980Z Pharmanovia takes on Impact's senaparib outside US, China for EUR 423.5m https://allsci.com/news/clinical-trials/ziltivekimab-zeus-trial-failure-novo-nordisks/ AllScien 2026-07-31T16:18:39.462972Z Novo's ziltivekimab misses cardiovascular endpoint despite biomarker success https://allsci.com/news/first-in-human-trials/car-t-therapy-autoimmune-create-medicines-gains/ AllScien 2026-07-31T16:04:56.250820Z CREATE clears Australian ethics review for first-in-human in vivo CAR-T study https://allsci.com/news/clinical-trials/scancell-neuphoria-merger-merges-with-nasdaq/ AllScien 2026-07-31T15:25:48.833144Z Scancell taps Nasdaq reverse merger to fund Phase III melanoma program